Prasugrel

Generic Name: Prasugrel

Brand Names: Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀FNO_₃S

CAS Number: 150322-43-3

Unique Ingredient Identifier: 34K66TBT99

Background: Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

Indication: 用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions: Cardiovascular Events

Associated Therapies: -

Clinical Trials

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease

Phase 2

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Prasugrel

First Posted Date: 2011-11-22

Last Posted Date: 2014-02-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 33

Registration Number: NCT01476696

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States

Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial

Phase 3

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Clopidogrel
Drug: prasugrel

First Posted Date: 2011-11-06

Last Posted Date: 2012-03-27

Lead Sponsor: Gennaro Sardella

Target Recruit Count: 30

Registration Number: NCT01465828

Locations: 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy

Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)

Phase 4

Completed

Conditions: Platelet Reactivity

Interventions: Drug: Clopidogrel
Drug: Prasugrel

First Posted Date: 2011-11-01

Last Posted Date: 2012-07-11

Lead Sponsor: University of Patras

Target Recruit Count: 27

Registration Number: NCT01463150

Locations: 🇬🇷
Cardiology Department Patras University Hospital, Rio, Achaia, Greece

Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Phase 4

Completed

Conditions: Platelet Reactivity

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2011-11-01

Last Posted Date: 2012-04-10

Lead Sponsor: University of Patras

Target Recruit Count: 50

Registration Number: NCT01463163

Locations: 🇬🇷
Cardiology Department Patras University Hospital, Rio, Achaia, Greece

Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing

Phase 4

Conditions: Coronary Heart Disease

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2011-10-20

Last Posted Date: 2013-11-01

Lead Sponsor: Deutsches Herzzentrum Muenchen

Target Recruit Count: 70

Registration Number: NCT01456364

Locations: 🇩🇪
Deutsches Herzzentrum, München, Bavaria, Germany
🇩🇪
Klinikum der Ludwig-Maximilians-Universität München, München, Bavaria, Germany
🇭🇺
Heart Center Balatonfüred, Dept. of Cardiology, Balatonfüred, Hungary

Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)

Phase 2

Completed

Conditions: STEMI

Interventions: Genetic: Point-of-Care Genetic Testing
Drug: Prasugrel

First Posted Date: 2011-10-14

Last Posted Date: 2013-04-25

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 102

Registration Number: NCT01452139

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study

Phase 4

Terminated

Conditions: Acute Coronary Syndrome
Cardiovascular Diseases

Interventions: Drug: clopidogrel
Drug: prasugrel

First Posted Date: 2011-10-14

Last Posted Date: 2022-03-16

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 9

Registration Number: NCT01452152

Locations: 🇺🇸
Christiana Care Health System, Newark, Delaware, United States
🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸
Sinai Center for Thrombosis Research, Baltimore, Maryland, United States

and more 2 locations

The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel

Phase 4

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Prasugrel

First Posted Date: 2011-06-03

Last Posted Date: 2020-09-09

Lead Sponsor: Medstar Health Research Institute

Target Recruit Count: 77

Registration Number: NCT01365221

Locations: 🇺🇸
The Heart Center, Huntsville, Alabama, United States
🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
Sinai Center for Thrombosis Research, Baltimore, Maryland, United States

and more 1 locations